Frontier Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Frontier Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-567,066	Closed	-$4.07M	–	290
2019 Q2	$4.07M	Sell	567,066 -233,715	-29%	-$2.39M	0.03%	267
2019 Q1	$11.3M	Sell	800,781 -1,649,433	-67%	-$21.8M	0.08%	226
2018 Q4	$33.2M	Sell	2,450,214 -426,153	-15%	-$7.68M	0.27%	133
2018 Q3	$63.8M	Buy	2,876,367 +777,764	+37%	+$16.4M	0.41%	88
2018 Q2	$34.4M	Buy	+2,098,603	New	+$36.8M	0.24%	152

Other funds holding AMRX

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Frontier Capital Management's AMRX Position: Q3 2019 in Review

Frontier Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 567,066 shares — an estimated $4.07M sold.

Frontier Capital Management first reported a position in AMRX in Q2 2018 and held it in 5 quarters. The position peaked at $63.8M in Q3 2018. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

Frontier Capital Management reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Frontier Capital Management sold 567,066 Amneal Pharmaceuticals shares in Q3 2019, an estimated $4.07M.
Frontier Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 5 quarters.
Frontier Capital Management's Amneal Pharmaceuticals position peaked at $63.8M in Q3 2018.
121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Frontier Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.